EN DE
Watch VICPLAS INTERNATIONAL LTD for free: we tell you when fair value or trend changes.
Data-driven stock valuation

VICPLAS INTERNATIONAL LTD (569) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of VICPLAS INTERNATIONAL LTD stock S$0.04, price S$0.06, that is 41.9% below the price, quality 44 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SG · ISIN SG1G57870584

VI VICPLAS INTERNATIONAL LTD logo Thin data Nov 15, 2026

VICPLAS INTERNATIONAL LTD

569 · SG

Far too expensive (fair value 42% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Quality 44/100 
Mixed Growth (revenue 5y +2.2 %/yr in SGD) 
Changed on Oct 30: S$0.0618 → S$0.0360 
Fair value 0.0360 SGD · Strongly overvalued 
Falling price (downtrend) 
Loss-making · -3.9% net margin (TTM) 
Negative free cash flow 
Trails peers (3/11) 
Narrow moat 13/100 · thin data
Thin data 
⚠ Thinly traded
Watch VICPLAS INTERNATIONAL LTD for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.2500 SGD 0.0600 SGD Fair Value 0.0360 SGD Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range 0.0600 SGD – 0.2500 SGD · the 0.0620 SGD price screens above the 0.0360 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow VICPLAS INTERNATIONAL in your weekly email

Every Wednesday you see whether VICPLAS INTERNATIONAL is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vicplas International Ltd, an investment holding company, engages in the medical devices, and pipes and pipe fittings businesses in Singapore, Malaysia, the People's Republic of China, the United Kingdom, and Mexico.

Show moreShow less

The company manufactures, trades, and distributes piping systems for various industries, including waste and potable water systems for residential homes, schools, and commercial and industrial buildings; underground electrical and internal building wire piping systems; and data and signal line piping systems by telecommunications companies.

It also designs, develops, manufactures, and assembles sterile and non-sterile medical devices. Vicplas International Ltd was founded in 1993 and is based in Singapore. Vicplas International Ltd is a subsidiary of Venner Capital S.A.

Stock analysis

VICPLAS INTERNATIONAL LTD (569) currently trades at 0.0620 SGD, while our model-based Fair Value estimate is 0.0360 SGD, 42% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

VICPLAS INTERNATIONAL LTD reported revenue of 127M SGD in FY2026 versus 114M SGD in FY2021, a compound +2.2%/yr. Reported net income was −5.1M SGD in FY2026.

Key figures

Market cap 31.7M SGD (≈ $24.6M) Micro · P/S ratio 0.25 · EPS (TTM) −0.0100 SGD · Net margin −3.9% · Return on equity −7.4% · Return on assets (EBIT) 0.1% (4-year average) · Operating margin 0.7% · Revenue (TTM) 131M SGD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (low confidence).

What moves the price

The share trades about 36% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −42%, 569 screens richer than that median.

Fair Value models

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA n/a 0.0200 SGD 0.0400 SGD 62
All 1 models by family
Multiples
EV/EBITDA n/a 0.0200 SGD 0.0400 SGD 62

Open the full fair value analysis →

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 30
How much profit the company makes from its sales and capital
Quality Growth 49
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 41
Debt, balance sheet and risk of trouble
Investment 89
Does it invest with discipline instead of growing at any price?
Low Volatility 61
How calm the share price moves, does not count
Price momentum 11
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 8/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.2%
Start year 2021 (pandemic). Over 10 years: +5.3% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
6.0% (2021) → −4.5% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

569 screens overvalued: fair value 42% below the price. Compare with Abbott Laboratories, →

Compare VICPLAS INTERNATIONAL LTD with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Below median
Fair Value upside −40.0% · Bottom 25%
Profitability
Return on assets −3.5% · Below median
Net margin (12 months) −3.9% · Below median
Operating margin (12 months) 0.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) 5.0% · Below median
Balance sheet
Debt / equity 0.11× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.45× · Cheapest 25%
P/S (12 months) 0.23× · Cheapest 25%
EV/EBITDA 6.6× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)25 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)95 · sector 97
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $309.64 $340.60 +10% vs 569
Boston Scientific Corporation BSX $44.34 $48.77 +10% vs 569
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥179.40 ¥197.34 +10% vs 569
DexCom, Inc DXCM $83.33 $91.66 +10% vs 569
STERIS plc STE $264.32 $281.90 +7% vs 569
GE HealthCare Technologies Inc GEHC $83.02 $69.92 −16% vs 569
Edwards Lifesciences Corporation EW $107.15 $81.94 −24% vs 569
Medtronic plc MDT $102.86 $74.90 −27% vs 569
Abbott Laboratories, ABT $108.52 $75.28 −31% vs 569
Koninklijke Philips N.V PHIA €27.43 €15.23 −44% vs 569

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

VICPLAS INTERNATIONAL LTD: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "VICPLAS INTERNATIONAL LTD Fair Value". https://www.fairvalue-calculator.com/stock/569

Frequently asked questions

Is VICPLAS INTERNATIONAL LTD (569) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of 0.0360 SGD versus a price of 0.0620 SGD, about 42% lower (overvalued).
What is the fair value of 569?
Our model-based fair value for VICPLAS INTERNATIONAL LTD is 0.0360 SGD (as of Nov 15, 2026), built from audited fundamentals. The current price: 0.0620 SGD.
What is the quality score of 569?
VICPLAS INTERNATIONAL LTD has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for VICPLAS INTERNATIONAL LTD (569)?
Our model-based price target is the fair value of 0.0360 SGD (as of Nov 15, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the VICPLAS INTERNATIONAL LTD stock forecast for 2026?
Our models put fair value at 0.0360 SGD, about 42% lower versus a price of 0.0620 SGD (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of VICPLAS INTERNATIONAL LTD (569)?
VICPLAS INTERNATIONAL LTD reported trailing-twelve-month revenue of about 131M SGD (latest available figure, as of Nov 15, 2026).
What is the intrinsic value of VICPLAS INTERNATIONAL LTD (569)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For VICPLAS INTERNATIONAL LTD it is 0.0360 SGD per share (as of Nov 15, 2026), against a price of 0.0620 SGD. It is the blended result of 1 valuation models in 1 family (Multiples).
Is VICPLAS INTERNATIONAL LTD stock overvalued or undervalued in 2026?
As of Nov 15, 2026, 569 trades above its calculated fair value: price 0.0620 SGD, fair value 0.0360 SGD, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 569?
No. The price is what the market pays today (0.0620 SGD); the fair value is what the company's own numbers justify (0.0360 SGD). For VICPLAS INTERNATIONAL LTD the two are 0.0260 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is VICPLAS INTERNATIONAL LTD worth?
The market values VICPLAS INTERNATIONAL LTD at about 31.7M SGD (market capitalisation, as of Nov 15, 2026). Per share that is 0.0620 SGD; our models calculate a fair value of 0.0360 SGD per share.
How solid is the balance sheet of VICPLAS INTERNATIONAL LTD (569)?
Balance-sheet figures for VICPLAS INTERNATIONAL LTD (as of Nov 15, 2026): return on equity −7.4%, debt of 0.11 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 569 from its 52-week high?
VICPLAS INTERNATIONAL LTD trades at 0.0620 SGD, about 36% below its 52-week high of 0.0970 SGD and 3% above the low of 0.0600 SGD (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0360 SGD is for.
Which stocks are comparable to VICPLAS INTERNATIONAL LTD?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is VICPLAS INTERNATIONAL LTD stock attractive at the current price?
The data as of Nov 15, 2026: price 0.0620 SGD, calculated fair value 0.0360 SGD (−42%), Quality Score 44/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 569 calculated?
We run VICPLAS INTERNATIONAL LTD through 1 models from 1 family: Multiples. Every model gets the same audited fundamentals; the fair value of 0.0360 SGD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. VICPLAS INTERNATIONAL LTD itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of VICPLAS INTERNATIONAL LTD (569)?
The closing price on Nov 16, 2026 was 0.0620 SGD. Our model-based fair value is 0.0360 SGD, about 42% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with VICPLAS INTERNATIONAL LTD right now?
Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of VICPLAS INTERNATIONAL LTD

How large is the market capitalisation of VICPLAS INTERNATIONAL LTD (569)?
The market capitalisation of VICPLAS INTERNATIONAL LTD is 31.7M SGD (≈ $24.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of VICPLAS INTERNATIONAL LTD (569)?
The price-to-sales ratio of VICPLAS INTERNATIONAL LTD is 0.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of VICPLAS INTERNATIONAL LTD (569)?
Earnings per share at VICPLAS INTERNATIONAL LTD are −0.0100 SGD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of VICPLAS INTERNATIONAL LTD (569)?
The net margin of VICPLAS INTERNATIONAL LTD is −3.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of VICPLAS INTERNATIONAL LTD (569)?
The return on equity (ROE) of VICPLAS INTERNATIONAL LTD is −7.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of VICPLAS INTERNATIONAL LTD (569)?
On an EBIT basis the return on assets of VICPLAS INTERNATIONAL LTD is 0.1% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of VICPLAS INTERNATIONAL LTD (569)?
The operating margin of VICPLAS INTERNATIONAL LTD is 0.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at VICPLAS INTERNATIONAL LTD (569)?
Revenue at VICPLAS INTERNATIONAL LTD is growing 5.0% versus a year earlier (3y avg −0.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at VICPLAS INTERNATIONAL LTD (569)?
Earnings per share at VICPLAS INTERNATIONAL LTD are growing 20.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does VICPLAS INTERNATIONAL LTD (569) generate?
The free cash flow of VICPLAS INTERNATIONAL LTD is −4.1M SGD (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does VICPLAS INTERNATIONAL LTD (569) carry?
The net debt of VICPLAS INTERNATIONAL LTD is 29.4M SGD (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch VICPLAS INTERNATIONAL LTD in the live analysis

One click puts VICPLAS INTERNATIONAL LTD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.